Drug Profile
Topotecan liposomal - Assertio Therapeutics
Alternative Names: Brakiva; INX-0076; Liposomal topotecan; Optisomal topotecan; Sphingosome-encapsulated topotecan; Topotecan liposome injection; Topotecan-TCSLatest Information Update: 12 Jan 2024
Price :
$50
*
At a glance
- Originator Inex Pharmaceuticals Corporation
- Developer Assertio Therapeutics
- Class Antineoplastics; Camptothecins; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ovarian cancer; Small cell lung cancer
Most Recent Events
- 18 May 2016 No recent reports of development identified - Phase-I for Small cell lung cancer (Late-stage disease, Second-line therapy or greater) in USA (IV)
- 18 May 2016 No recent reports on development identified - Phase-I for Ovarian cancer (Late-stage disease, Second-line therapy or greater) in USA (IV)
- 18 Jul 2013 Spectrum Pharmaceuticals acquires Talon Therapeutics' previous rights to liposomal topotecan